Cerliponase alfa 150mg/5ml solution for infusion vials
NHS hospitals in England used £15,220,999 of indicative cost of Cerliponase alfa 150mg/5ml solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 10.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Cerliponase alfa 150mg/5ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Cerliponase alfa 150mg/5ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Manchester University Nhs Ft | £8,022,693 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,327,062 |
| Univ Hpls Bristol Nhs Foundation Trust | £1,045,564 |
| Birmingham Womans & Childrens Nhs Ft | £683,638 |
| Salford Royal Nhs Foundation Trust | £542,889 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.